Enovis (NYSE:ENOV – Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $555.14 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Enovis Stock Down 2.6 %
NYSE:ENOV opened at $42.77 on Monday. Enovis has a 1-year low of $38.27 and a 1-year high of $65.03. The company has a 50-day moving average of $45.08 and a 200 day moving average of $44.38. The firm has a market cap of $2.43 billion, a PE ratio of -19.53 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC reissued a “buy” rating and set a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Articles
- Five stocks we like better than Enovis
- The Most Important Warren Buffett Stock for Investors: His Own
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- How to Most Effectively Use the MarketBeat Earnings Screener
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- The How and Why of Investing in Gold Stocks
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
